| Literature DB >> 23668556 |
Mingzhao Xing1, Bryan R Haugen, Martin Schlumberger.
Abstract
Substantial developments have occurred in the past 5-10 years in clinical translational research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules. BRAF mutation is a prognostic genetic marker that has improved risk stratification and hence tailored management of patients with thyroid cancer, including those with conventionally low risks. Novel molecular-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials; such treatments are likely to become a component of the standard treatment regimen for patients with thyroid cancer in the near future. These novel molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting developments in this unprecedented era of molecular thyroid-cancer medicine.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23668556 PMCID： PMC3931461 DOI： 10.1016/S0140-6736(13)60109-9
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321